印第安纳州与辉瑞Viatris就价格纵指控达成625万美元的EpiPen反垄断诉讼和解。 Indiana settles 2025 EpiPen antitrust lawsuit with Pfizer, Viatris for $6.25M over price-fixing allegations.

印第安纳州已经解决了对包括瑞和维亚特里斯在内的制药公司的2025年反断诉讼,指控他们通过反竞争策略将EpiPen价格膨胀超过600%,例如支付药房福利经理来阻止竞争对手,并推广多包而不是单个单元. Indiana has settled a 2025 antitrust lawsuit against pharmaceutical companies, including Pfizer and Viatris, over allegations they inflated EpiPen prices by over 600% through anti-competitive tactics like paying pharmacy benefit managers to block rivals and promoting multi-packs over single units. 公司否认不法行为的625万美元的和解解决了违反国家消费者保护、反托拉斯和医疗补助欺诈法的指控。 The $6.25 million settlement, which the companies deny wrongdoing, resolves claims of violating state consumer protection, antitrust, and Medicaid fraud laws. 资金将支持降低国家医疗费用的努力。 Funds will support efforts to reduce healthcare costs in the state.